Alnylam Pharmaceuticals Stock Filter Stocks by Fundamentals
| ALNY Stock | USD 250.98 6.09 2.49% |
Alnylam Pharmaceuticals fundamentals help investors to digest information that contributes to Alnylam Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alnylam Stock. The fundamental analysis module provides a way to measure Alnylam Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alnylam Pharmaceuticals stock.
Alnylam | Shares Owned by Institutions |
Alnylam Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alnylam Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alnylam Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Alnylam Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Alnylam Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alnylam Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alnylam Pharmaceuticals' value.| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 3.1 M | Norges Bank | 2024-06-30 | 2.3 M | Geode Capital Management, Llc | 2024-09-30 | 2.1 M | Jpmorgan Chase & Co | 2024-06-30 | 1.8 M | American Century Companies Inc | 2024-09-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.5 M | Orbis Allan Gray Ltd | 2024-09-30 | 1.3 M | Legal & General Group Plc | 2024-06-30 | 926.3 K | Bellevue Group Ag | 2024-09-30 | 809.1 K | Capital World Investors | 2024-09-30 | 16.5 M | Fmr Inc | 2024-09-30 | 14.7 M |
Alnylam Fundamentals
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0292 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 30.11 B | ||||
| Shares Outstanding | 128.98 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Shares Owned By Institutions | 98.05 % | ||||
| Number Of Shares Shorted | 3.7 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 976.27 X | ||||
| Price To Sales | 15.08 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 868.6 M | ||||
| EBITDA | (258.24 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Short Ratio | 4.60 X | ||||
| Earnings Per Share | (2.62) X | ||||
| Price To Earnings To Growth | (0.49) X | ||||
| Target Price | 301.21 | ||||
| Number Of Employees | 2.1 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 31.59 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
| Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.